# A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

> **NCT02033889** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 621 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Ertugliflozin 5 mg
- **DRUG:** Ertugliflozin 15 mg
- **DRUG:** Placebo to Ertugliflozin
- **OTHER:** Glimepiride
- **DRUG:** Placebo to Glimepiride
- **BIOLOGICAL:** Basal Insulin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02033889
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-13
- **Primary completion:** 2017-08-03
- **Final completion:** 2017-08-03
- **Target enrollment:** 621 (ACTUAL)
- **Last updated:** 2018-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02033889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02033889, "A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02033889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*